Articles tagged with Liver Cancer
A large study found no significant difference in liver cancer recurrence between patients treated with direct-acting antivirals for hepatitis C. The treatment was also shown to reduce the aggressiveness of cancer when it did recur. This new data reassures providers that treating Hep C is safe and beneficial for these patients.
Researchers develop a novel approach to target aggressive liver cancer by inhibiting protein production, leaving healthy cells unharmed. The study shows promising results using a genetic approach and a drug that directly inhibits translation, slowing tumor growth and blocking immune evasion.
The US cancer death rate has declined by 27% since 1991, primarily due to reductions in smoking and advances in early detection and treatment. Despite this progress, socioeconomic inequalities have widened, with poorer counties experiencing a disproportionate burden of preventable cancers.
A team of researchers at Boston Children's Hospital has identified NUAK2 as a critical player in the Hippo pathway, which drives YAP-driven tumors. Inactivating NUAK2 with a small molecule compound strongly curbs cancer cell proliferation and liver overgrowth.
A new study finds Transarterial Radioembolization with Yttrium-90 (TARE-Y90) effective and feasible in children with difficult-to-treat liver cancer. The treatment offers a less toxic alternative for patients who have not responded to chemotherapy.
A preclinical study found that inhibiting liver cancer cell growth can be achieved by manipulating the circadian clock. Fifty percent of liver tumors express a malfunctioning protein that induces circadian dysfunction, and forcing tumor cells to re-express this protein leads to their death.
A new study from Monash University and Peter MacCallum Cancer Centre has found a previously overlooked group of obese individuals may be at risk of developing deadly liver cancer. The research explains how obesity is linked to liver cancer, with current screening guidelines potentially missing these high-risk patients.
Researchers found that adding refined fiber to processed foods can lead to liver cancer in mice with preexisting gut dysbiosis. The study suggests that enriching foods with purified fibers may not replicate the health benefits of whole foods naturally rich in fiber.
A new study from UTledo's College of Medicine and Life Sciences found a link between refined dietary fiber, gut bacteria, and liver cancer. The research suggests that consuming highly refined soluble fibers in processed foods may pose health risks, particularly for individuals with gut bacterial overgrowth or dysbiosis.
The report emphasizes tobacco control as the top priority in a national cancer control plan due to its significant health benefits. Tobacco use remains the leading cause of preventable cancer deaths, accounting for nearly 30% of all cancer-related deaths in the US.
The report reveals a high burden of prostate and colorectal cancers among Hispanic men in Puerto Rico, contrasting with lower rates among non-Hispanic whites. The study emphasizes the need for culturally tailored strategies to address these disparities and promote healthy lifestyle behaviors.
A study led by Paul Brindley is examining the cellular link between liver fluke and cholangiocarcinoma, a rare but aggressive form of cancer. The research aims to understand why worm infections cause liver cells to transform into cancer.
Scientists discover TREM-1 amplifies inflammation, leading to liver scarring and cirrhosis. Targeting this receptor may prevent fibrosis and cancer development.
A study analyzing NY state cancer death data from 2008-2014 found high mortality rates among U.S.-born blacks and Puerto Ricans, while South American Hispanics had relatively low rates. The researchers also identified significant disparities in liver cancer mortality between these groups.
A new study published in Diabetologia reveals that diabetes is a significant risk factor for all-site and site-specific cancers, with a higher risk in women than men. Women with diabetes have a 27% higher risk of all-site cancer compared to women without diabetes.
A study found a 65% increase in cirrhosis deaths and a doubling of liver cancer deaths among US adults between 1999 and 2016. Young people aged 25-34 experienced the highest average annual increase in cirrhosis deaths, driven by alcohol-related liver disease.
A study published in Communications Biology has linked the protein PARP1 to an aggressive form of pediatric liver cancer called hepatoblastoma. Researchers found that inhibiting PARP1 slowed or stopped cancer progression in laboratory tests, providing a potential treatment target for this disease.
Researchers at Mayo Clinic have developed a DNA test that can detect liver cancer with high accuracy, outperforming current methods. The test uses abnormal DNA markers found in liver cancer tissues and has been shown to detect over 90% of patients with curable stage tumors.
A new clinical trial is testing whether omega-3 capsules can stop bowel cancer from returning after liver surgery. The trial, funded by Yorkshire Cancer Research, involves 450 patients and investigates the effectiveness of a highly purified form of EPA.
A study confirms a curable state between single and widespread cancers by identifying molecular patterns that predict patient outcomes. Researchers found that patients with limited spread of disease could achieve prolonged survival with surgery or targeted radiation therapy.
The number of people receiving HCV cure is increasing with new, highly effective treatments available; simplification of treatment delivery can accelerate global scale-up. Cure leads to reductions in liver-related deaths and cancer risk, as well as improvements in comorbidities.
Researchers discovered mouse genes that enhance human T-cell power against liver cancer, offering new hope for patients. Engineered human T cells eradicated cancer without harming normal liver tissue.
Researchers identified a tumor suppressor protein called LHPP that can help diagnose and monitor liver cancer. Reintroducing LHPP into the liver of model mice prevented tumor formation, suggesting its potential as a new therapeutic approach for treating liver cancer.
Patients with alcohol-related liver cancer tend to have poorer overall survival rates compared to those with non-alcohol related liver cancer. The study highlights the need for improved screening and treatment programs for patients at risk of developing cirrhosis or liver cancer, especially those who are still drinking.
A recent study found that less than 13% of individuals born between 1945 and 1965 have undergone HCV screening. The researchers also noted a significant disparity in HCV screening rates among different ethnic groups, with Hispanics and non-Hispanic Blacks receiving lower rates of screening.
A large study of Japanese adults found a significant association between higher vitamin D levels and a lower risk of overall cancer, including liver cancer. The researchers observed a reduced relative risk of around 20% for overall cancer and 30-50% for liver cancer.
Researchers have developed a method to identify splicing-based biomarkers for hepatocellular carcinoma (HCC), the most common form of liver cancer. These biomarkers may help predict disease progression and are associated with poor patient survival.
Combining a blood test for high alpha fetoprotein (AFP) levels with ultrasound imaging improves liver cancer detection by 40 percent, according to researchers at UT Southwestern Medical Center. Early detection is crucial for improving survival rates in patients with liver cancer, which is on the rise in the US.
Researchers discovered that polyploid liver cells can protect the liver against cancer by carrying extra copies of tumor suppressor genes. This finding challenges the notion that polyploidy is a pro-cancer state and suggests it could be an adaptive response within normal liver cells.
Researchers have developed a new method to grow patient-derived xenografts (PDX) liver cancer cells in culture, which maintains their proper shape and function and grows as organoids. The success of the engineered organoids has the potential to revolutionize the screening and development of liver cancer drugs.
Researchers discover a two-step process to kill liver cancer cells by silencing an enzyme and adding metformin, potentially accelerating new treatments for this deadly disease. This approach has shown promise in treating liver cancer, where surgery is often not an option and available drugs are only moderately effective.
A study published in The Lancet Diabetes & Endocrinology found that diabetes and high BMI were responsible for 544,300 new cancer cases globally in 2012. The authors project a significant increase in the proportion of cancers attributable to these risk factors, particularly in low- and middle-income countries.
A study of over 200 studies found that moderate coffee drinking is associated with lower risks of death, heart disease, and certain cancers. However, high consumption during pregnancy or in women at risk of fracture may be detrimental. The authors suggest further randomized trials to confirm the findings.
Researchers discovered a synthetic double-stranded RNA that boosts anti-tumor innate immune functions, potentially preventing liver cancer. The study found that administering the RNA at different stages suppressed tumor formation in mouse models.
Researchers at the University of California San Diego School of Medicine found that chronic liver inflammation suppresses immunosurveillance, allowing cancer cells to grow. Inhibiting PD-L1 restored immune function and cleared tumors in mice with NASH-associated mutations.
Research shows long-term aspirin use significantly reduces digestive cancer incidence, with substantial reductions in liver and oesophageal cancers. Aspirin use also shows promise in reducing risk of certain other cancers, while raising cardiovascular risk when stopped.
A study by researchers from Duke-NUS Medical School and Taiwan found that liver cancers exposed to Aristolochic Acids have AA-related mutations, with high prevalence in East and Southeast Asia. The findings highlight the need for public education and awareness about the dangers of AA in herbal products.
A study published in Gastroenterology identifies the gene mutation responsible for fibrolamellar hepatocellular carcinoma, a rare form of liver cancer mainly affecting children and young people. The researchers used CRISPR/Cas9 technology to introduce the mutation into mice, resulting in 12 out of 15 developing tumors.
A USC research team has identified a potential therapeutic target for liver cancer treatment: mitophagy, the removal of damaged mitochondria. This process can cause tumors to proliferate, but temporarily halting it may reduce cancer stem cell growth, leading to tumor regression.
A new study estimates that there were 854,000 new cases of liver cancer and 810,000 deaths worldwide in 2015. The majority of these cases were attributed to hepatitis B virus and alcohol consumption, highlighting the need for prevention and treatment strategies.
Researchers found two types of T cells respond differently to cancer antigens, with one starting strong but exhausting quickly and the other staying on target for a longer antitumor effect. The study suggests that targeting the persistent T cell type could lead to more effective cancer vaccines.
A recent study found that chronic cell death promotes the development of liver cancer by causing remaining cells to divide at higher rates. The researchers also identified caspase 8 as an enzyme playing a dual role in this process, involving both apoptosis and DNA repair.
Researchers discovered that caspase-8 triggers programmed cell death in diseased liver cells, leading to genetic instability and tumor development. This mechanism is remarkably universal across various liver diseases.
Researchers at KAIST have developed a novel method to improve medication treatment for liver cancer, identifying the resistance mechanism of Sorafenib and discovering a new approach to block it. The study suggests the possibility of developing a new method to overcome drug resistance using network analysis.
Researchers have developed a rapid portable test for liver cancer that can detect the disease in two minutes and can be administered wherever the patient is. The test uses gold nanoparticles to trap biomarkers from biological fluids, making it a potential game-changer in combating this deadly disease.
A little-studied gene SLC13A5 may explain how liver cancer cells obtain energy to proliferate. Suppressing SLC13A5 in human hepatocellular carcinoma cell lines resulted in slower growth and division of cancer cells.
Researchers at the University of Missouri found that women with increased cadmium levels have a higher risk of endometrial cancer, with rates increasing by 22% in individuals with elevated levels. The study recommends limiting cadmium intake through diet and lifestyle changes to reduce associated cancer risks.
Inlighta Biosciences is developing a novel, protein-based MRI contrast agent called ProCA32 to detect early stages of liver cancers and other metastatic tumors. The agent has shown improved imaging contrast compared to conventional agents, enabling earlier detection and characterization of cancerous lesions.
Researchers identified a key signaling pathway causing bile duct cancer and found possibilities to interrupt it. High ROS levels and TNF production promote tumor growth, but antioxidants and JNK inhibitors can stop tumorigenesis.
Exposure to particulate air pollution after liver cancer diagnosis significantly increases risk of premature death. Higher exposure levels further elevate the risk of dying from liver cancer or any cause.
In liver cancer, Scrib's increased expression suppresses the growth of cancer cells by inhibiting three oncogenes. The study provides the first hard evidence that Scrib functions as a tumor suppressor in human and animal liver cancer.
The CheckMate 040 study found that nivolumab produces durable responses with long-term survival rates of up to 59.9% in sorafenib-experienced patients with advanced HCC, regardless of Hepatitis B or C infection status.
Sub-Saharan African-born blacks experience a higher incidence of infection-related cancers and blood cancers compared to US-born non-Hispanic blacks. In contrast, prostate cancer is more prevalent among Western African-born black men, while Eastern African-born blacks have higher rates of liver and thyroid cancer.
Research identifies PPARγ as a critical regulator of metabolism-associated genes in the liver. Inhibition of PPARγ suppresses tumor growth and reduces tumorigenesis in mouse models.
Researchers developed a novel therapy using iPS-cell derived immune cells that produce interferon-β to combat liver cancer. The treatment was found to inhibit tumor cell proliferation and cause death, with high concentrations of IFN-β detected at targeted sites.
Researchers at MIT have developed a way to detect aflatoxin exposure by sequencing DNA of liver cells, potentially leading to earlier diagnosis and treatment. The technique can identify rare mutations caused by aflatoxin long before tumors form.
Sanford Simon at Rockefeller University has received a $600,000 grant from the Fibrolamellar Cancer Foundation to develop a therapy for fibrolamellar hepatocellular carcinoma. The disease typically affects adolescents and young adults with no history of liver disease, and there is currently no standard treatment regimen.
A new study published in Diabetologia found that having type 2 diabetes increases the risk of death from any form of cancer by 26%, even when controlling for other factors. The research also revealed statistically significant links between T2D and specific cancers, including liver, pancreas, breast, kidney, and endometrium.
A recent study discovered that liver cancer drugs fail because the body lacks a balance between two enzymes, Shp2 and Pten. This imbalance activates molecules involved in lipid metabolism, inflammation, and fibrosis, leading to liver disease and cancer.
A new study found that cancer cases are growing at an alarming rate in less developed countries, with a 50% increase between 2005 and 2015. The global burden of disease is heaviest for countries with high development levels, but the most rapid escalation can be seen in low-income nations where health services are often lacking.